BioXcel Therapeutics (BTAI) grants director 17,000 options in Form 4 filing

Rhea-AI Filing Summary

BioXcel Therapeutics director June Bray reported a grant of 17,000 stock options. The options give her the right to buy 17,000 shares of BioXcel Therapeutics common stock at an exercise price of $2.01 per share, based on a grant dated January 9, 2026. Following this award, she beneficially owns 17,000 derivative securities in the form of these options, held directly.

According to the vesting terms, the option will become exercisable on the earlier of the first anniversary of the grant date or the day immediately before the next annual meeting of stockholders after the grant date, as long as she continues to serve as a non-employee director through that vesting date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Bray June

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	17,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 17,000 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bray June

(Last) (First) (Middle)

C/O BIOXCEL THERAPEUTICS, INC.

555 LONG WHARF DRIVE, 12TH FLOOR

(Street)

NEW HAVEN CT 06511

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BioXcel Therapeutics, Inc. [ BTAI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.01	01/09/2026		A		17,000		(1)	01/09/2036	Common Stock	17,000	$0	17,000	D

Explanation of Responses:

1. The option shall vest and become exercisable on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case, subject to the Reporting Person's continuing in service as a non-employee director through such vesting date.

	/s/ Richard Steinhart, Attorney-in-Fact for June Bray	01/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did BioXcel Therapeutics (BTAI) report in this Form 4?

The filing reports that director June Bray received a grant of 17,000 stock options to purchase BioXcel Therapeutics common stock.

How many stock options were granted to BioXcel Therapeutics (BTAI) director June Bray?

Director June Bray was granted 17,000 stock options, and she beneficially owns 17,000 derivative securities after this transaction.

What is the exercise price of June Bray’s BioXcel Therapeutics (BTAI) stock options?

The stock options granted to June Bray have an exercise price of $2.01 per share for BioXcel Therapeutics common stock.

When do the BioXcel Therapeutics (BTAI) options granted to June Bray vest?

The options vest on the earlier of the first anniversary of the grant date or the day immediately before the next annual meeting of stockholders after the grant date, if she continues serving as a non-employee director.

Is June Bray’s ownership in BioXcel Therapeutics (BTAI) reported as direct or indirect?

The 17,000 stock options held by June Bray are reported as direct beneficial ownership.

What type of security is reported in this BioXcel Therapeutics (BTAI) Form 4?

The filing reports a Stock Option (Right to Buy), which is a derivative security giving the holder the right to purchase common stock at a fixed exercise price.